```json
{
"content": [
{
"type": "paragraph",
"content": "The Pemetrexed market refers to the global commercialization of pemetrexed-based therapies, primarily used in the treatment of non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma. As a key chemotherapeutic agent, pemetrexed plays a critical role in oncology care, with its market size and growth outlook closely tied to cancer prevalence, drug innovation, and regulatory dynamics. The industry expansion is driven by increasing demand for targeted therapies, advancements in combination treatments, and the rising incidence of respiratory cancers globally."
},
{
"type": "chart",
"chartType": "segment-stacked",
"data": {
"segments": ["Alimta (Eli Lilly)", "Generics", "Biosimilars"],
"periods": ["2021", "2022", "2023", "2024", "2025", "2026", "2027", "2028", "2029", "2030", "2031", "2032", "2033"],
"values": [
[1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, 1800], // Alimta
[500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100], // Generics
[100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 320, 340] // Biosimilars
]
}
},
{
"type": "paragraph",
"content": "The Pemetrexed market size is estimated at $1.2 billion in 2026, with a projected CAGR of 6.5% from 2026 to 2033. Key growth drivers include the rising adoption of first-line therapies for NSCLC, accelerated approvals of biosimilars, and growing adoption in emerging markets. However, pipeline competition and pricing pressures in mature markets may moderate expansion. North America remains the largest region, while Asia-Pacific is the fastest-growing due to expanding healthcare infrastructure and rising awareness. Strategic collaborations for combination therapies and regulatory support for orphan drug designations are pivotal forces reshaping the industry landscape."
}
]
}
```
